An animal model to study the molecular basis of tardive dyskinesia

Methods in Molecular Biology

Volumn 829, Issue , 2012, Pages 193-201

  Bishnoi, Mahendra ^a   Boparai, Ravneet K ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Caspase 3; Haloperidol; Inflammation; Oxidative damage; Tardive dyskinesia

Indexed keywords

21 [4 [5,6 BIS(DIETHYLAMINO) 2 PYRIDYL] 1 PIPERAZINYL] 16ALPHA METHYLPREGNA 1,4,9(11) TRIENE 3,20 DIONE; CASPASE 3; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PREGNANE DERIVATIVE;

ANIMAL; ANIMAL BEHAVIOR; APOPTOSIS; ARTICLE; DISEASE MODEL; DRUG EFFECT; DYSKINESIA; HUMAN; MALE; METABOLISM; MOTOR DYSFUNCTION; RAT; WISTAR RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOPTOSIS; BEHAVIOR, ANIMAL; CASPASE 3; CLOZAPINE; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; HUMANS; MALE; MOVEMENT DISORDERS; PREGNATRIENES; RATS; RATS, WISTAR;

ANIMALIA;

EID: 84856325761     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-458-2_12     Document Type: Article

References (13)

1. Creese, I.; Burt, D.; Snyder, S.H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192, 481-483.
2. Walker, J.M.; Bowen, W.D.; Walker, F.O.; Matsumoto, R.R.; De Costa, B.; Rice, C.K. (1990) Sigma receptors: biology and function. Pharmacol. Rev. 42, 355-402.
3. Vilner, B.J.; Costa, B.R.; Bowen, W.D. (1995) Cytotoxic effects of sigma ligands: Sigma receptor- mediated alterations in cellular morphology and viability. J Neurosci. 15, 117-134.
4. Meshul, C.K. and Tan, S.E, (1994) Haloperidolinduced morphological alterations are associated with changes in calcium/calmodulin kinase II activity and the glutamate immunoreactivity. Synapse. 18, 205-217. (Pubitemid 24357174)
5. Halliday, G.M.; Pond, S.M.; Cartwright, H.; McRitchie, D.A.; Castagnoli, N.; Van der Shyf, C.J. (1999) Clinical and neuropathological abnormalities in baboons treated with HPTP, tetrahydropyridine analog of haloperidol. Exp. Neurol. 158, 155-163. (Pubitemid 29344327)
6. Post, A.; Rucker, M.; Ohl, F.; Uhr, M.; Holsboer, F.; Almeida, O.F.; Michaelidis, T.M. (2002) Mechanisms underlying the protective potential of alpha-tocopherol (vitamin E) against haloperidol-associated neurotoxicity. Neuropsychopharmacology. 26, 397-407. (Pubitemid 34159217)
7. Sagara, Y. (1998) Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 71, 1002-1012. (Pubitemid 28390254)
8. Lohr, J.B.; Cadet, J.L.; Lohr, M.A.; Larson, L.; Wasli, E.; Wade, L.; Hylton, R.; Vidoni, C.; Jeste, D.V.; Wyatt, R.J. (1988) Vitamin E in the treatment of tardive dyskinesia: The possible involvement of free radical mechanism, Schizophr. Bull. 14, 291-296.
9. Wills, E.D. (1966) Mechanism of lipid peroxide formation in animal tissues. Biochem. Jour. 99, 667-676.
10. Babior, B.M.; Kipner, R.S.; Cerutte, J.T. (1973) Biological defense mechanism. The production by leukocytes of superoxide, a potential bacterial agent. J. Clin. Investigation. 52, 741-744.
11. Ellman, G.L. (1959) Tissue sulfhydryl groups. Arch. of Biochemi. Biophy. 82, 70-77.
12. Lowry, O.H. (1951) Protein measurements with the Folin-phenol reagent. J. Biol. Chem. 193, 265-275
13. Bishnoi, M.; Chopra, K.; Kulkarni, S.K. (2007) Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia-A biochemical and neurochemical study. Prog. Neuropsychopharmacol. Biol. Psychiatry. 31, 1130-1138. (Pubitemid 46810111)